Covid-19: Wits resumes participation in the Oxford's vaccine trials

play article
Subscribers can listen to this article
Wits University has resumed vaccine trials.
Wits University has resumed vaccine trials.
Sechenov Medical University Press OfficeTASS via
  • Wits University has resumed participation in the Oxford Covid-19 vaccine trial currently also underway in the UK, Brazil and the U.S.
  • Vaccination resumed in South Africa on Tuesday once the go-ahead was given by the SA Health Products Regulatory Authority and local ethics committees.
  • The leader of the SA trial said it was expected that some participants would become unwell and every case had to be carefully evaluated to ensure careful assessment of safety.

The University of the Witwatersrand announced that it has resumed participation in the Oxford Covid-19 vaccine trial currently also underway in the UK, Brazil and the US.

According to the university, the South African Health Products Regulatory Authority and local ethics committees this week approved resuming vaccination in South Africa.

In a statement, the university said that the Ox1nCov19 vaccine trial in the UK paused last week following a "medical event" in one trial participant there.

READ | Covid-19: Mkhize finally makes MAC recommendations public

"Professor Shabir Madhi, executive director of the Vaccines and Infectious Diseases Analytics Research Unit (VIDA) who leads the Ox1nCov19 trial in South Africa, confirmed today that vaccination resumed in South Africa on Tuesday, 15 September, once local regulatory and ethics committees had given the go-ahead," Wits spokesperson Deborah Minors said.

Madhi said the South African study was overseen by the same independent Data and Safety Monitoring Committee [DSMC] as in the UK, so all sites in South Africa had also paused vaccination when the UK did.

"The South African Health Products Regulatory Authority (SAHPRA) and Wits University ethics committees have now approved resuming vaccination, and we have done so," added Madhi.

The university said that globally, some 18 000 individuals received study vaccines as part of this trial.

Trials

However, in large trials such as this, it was expected that some participants would become unwell and every case had to be carefully evaluated to ensure careful assessment of safety.

"We cannot disclose medical information about the illness for reasons of participant confidentiality," the University of Oxford spokesperson said.

However, Wits assured that the DSMC review concluded that the event in the UK was unlikely to be related to the vaccination process.

"Pausing vaccination to review safety is evidence of the application of sound clinical practice and demonstrates the rigour of the independent oversight process under which this trial is being conducted," said Madhi. 

"Assessing the safety of the vaccine is the reason why studies such as these are essential in South Africa, before there is widespread use of the vaccine."

Lockdown For
DAYS
HRS
MINS
Voting Booth
Pyjamas or no pyjamas? Is sleeping in your day clothes:
Please select an option Oops! Something went wrong, please try again later.
Results
Disgusting!
63% - 2032 votes
Something I've seriously considered
10% - 334 votes
Normal in my household
27% - 879 votes
Vote
ZAR/USD
16.33
(-0.06)
ZAR/GBP
21.08
(-0.04)
ZAR/EUR
19.33
(-0.03)
ZAR/AUD
11.90
(-0.03)
ZAR/JPY
0.16
(-1.15)
Gold
1949.72
(+0.03)
Silver
26.74
(+0.09)
Platinum
928.80
(+0.44)
Brent Crude
43.52
(-0.32)
Palladium
2356.01
(+0.63)
All Share
54673.65
(-0.66)
Top 40
50399.16
(-0.59)
Financial 15
9841.32
(-2.14)
Industrial 25
72558.00
(-1.08)
Resource 10
55438.10
(+0.58)
All JSE data delayed by at least 15 minutes morningstar logo